首页> 美国卫生研究院文献>Molecules and Cells >EZH2-Mediated microRNA-139-5p Regulates Epithelial-Mesenchymal Transition and Lymph Node Metastasis of Pancreatic Cancer
【2h】

EZH2-Mediated microRNA-139-5p Regulates Epithelial-Mesenchymal Transition and Lymph Node Metastasis of Pancreatic Cancer

机译:EZH2介导的microRNA-139-5p调节胰腺癌的上皮-间质转化和淋巴结转移。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Pancreatic cancer (PC) is one of the most aggressive cancers presenting with high rates of invasion and metastasis, and unfavorable prognoses. The current study aims to investigate whether EZH2/miR-139-5p axis affects epithelial-mesenchymal transition (EMT) and lymph node metastasis (LNM) in PC, and the mechanism how EZH2 regulates miR-139-5p. Human PC and adjacent normal tissues were collected to determine expression of EZH2 and miR-139-5p, and their relationship with clinicopathological features of PC. Human PC cell line was selected, and treated with miR-139-5p mimics/inhibitors, EZH2 vector or shEZH2 in order to validate the regulation of EZH2-mediated miR-139-5p in PC cells. Dual-luciferase report gene assay and chromatin immunoprecipitation assay were employed to identify the relationship between miR-139-5p and EZH2. RT-qPCR and Western blot analysis were conducted to determine the expression of miR-139-5p, EZH2 and EMT-related markers and ZEB1/2. Tumor formation ability and in vitro cell activity were also analyzed. Highly-expressed EZH2 and poorly-expressed miR-139-5p were detected in PC tissues, and miR-139-5p and EZH2 expressions were associated with patients at Stage III/IV, with LNM and highly-differentiated tumors. EZH2 suppressed the expression of miR-139-5p through up-regulating Histone 3 Lysine 27 Trimethylation (H3K27me3). EMT, cell proliferation, migration and invasion were impeded, and tumor formation and LNM were reduced in PC cells transfected with miR-139-5p mimics and shEZH2. MiR-139-5p transcription is inhibited by EZH2 through up-regulating H3K27me3, thereby down-regulation of EZH2 and up-regulation of miR-139-5p impede EMT and LNM in PC. In addition, the EZH2/miR-139-5p axis presents as a promising therapeutic strategy for the treatment of PC.
机译:胰腺癌(PC)是最具侵袭性的癌症之一,表现为高浸润和转移率以及不良的预后。目前的研究旨在调查EZH2 / miR-139-5p轴是否影响PC的上皮-间质转化(EMT)和淋巴结转移(LNM),以及EZH2调控miR-139-5p的机制。收集人PC和邻近的正常组织,以确定EZH2和miR-139-5p的表达及其与PC临床病理特征的关系。选择人PC细胞系,并用miR-139-5p模拟物/抑制剂,EZH2载体或shEZH2处理,以验证EZH2介导的miR-139-5p在PC细胞中的调控。采用双荧光素酶报告基因检测法和染色质免疫沉淀检测法鉴定miR-139-5p与EZH2的关系。进行RT-qPCR和Western印迹分析,以确定miR-139-5p,EZH2和EMT相关标志物以及ZEB1 / 2的表达。还分析了肿瘤形成能力和体外细胞活性。在PC组织中检测到高表达的EZH2和低表达的miR-139-5p,并且miR-139-5p和EZH2表达与III / IV期,LNM和高分化肿瘤患者相关。 EZH2通过上调组蛋白3赖氨酸27三甲基化(H3K27me3)来抑制miR-139-5p的表达。在用miR-139-5p模拟物和shEZH2转染的PC细胞中,EMT,细胞增殖,迁移和侵袭受到阻碍,并且肿瘤形成和LNM减少。 EZH2通过上调H3K27me3来抑制MiR-139-5p转录,从而下调EZH2和miR-139-5p的上调阻碍了PC中的EMT和LNM。此外,EZH2 / miR-139-5p轴是治疗PC的有前途的治疗策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号